

Jorge Castillo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2150708/publications.pdf>

Version: 2024-02-01

369
papers

12,984
citations

19608

61
h-index

33814

99
g-index

370
all docs

370
docs citations

370
times ranked

10585
citing authors

#	ARTICLE	IF	CITATIONS
1	Natural history of Waldenström macroglobulinemia following acquired resistance to ibrutinib monotherapy. <i>Haematologica</i> , 2022, 107, 1163-1171.	1.7	11
2	An international, multicenter, retrospective study on the positive impact of cutaneous involvement on the clinical outcome of adult T-cell leukemia/lymphoma. <i>Leukemia and Lymphoma</i> , 2022, 63, 315-325.	0.6	4
3	Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenström macroglobulinemia. <i>Leukemia</i> , 2022, 36, 532-539.	3.3	50
4	POEMS Syndrome: Real World Experience in Diagnosis and Systemic Therapy - 108 Patients Multicenter Analysis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, 297-304.	0.2	11
5	Venetoclax in Previously Treated Waldenström Macroglobulinemia. <i>Journal of Clinical Oncology</i> , 2022, 40, 63-71.	0.8	53
6	Clonal hematopoiesis is associated with increased risk of progression of asymptomatic Waldenström macroglobulinemia. <i>Blood Advances</i> , 2022, 6, 2230-2235.	2.5	10
7	NCCN Guidelines® Insights: Multiple Myeloma, Version 3.2022. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 8-19.	2.3	80
8	Primary cutaneous Epstein-Barr virus-positive B-cell lymphoid proliferation with features of diffuse large B-cell lymphoma and mucocutaneous ulcer: a diagnostic dilemma. <i>International Journal of Dermatology</i> , 2022, , .	0.5	0
9	A British view on the management of Waldenström macroglobulinemia – Response to Pratt et al .. <i>British Journal of Haematology</i> , 2022, , .	1.2	0
10	Response and survival predictors in a cohort of 319 patients with Waldenström macroglobulinemia treated with ibrutinib monotherapy. <i>Blood Advances</i> , 2022, 6, 1015-1024.	2.5	12
11	SOHO State of the Art Updates and Next Questions: Targeted therapies and emerging novel treatment approaches for Waldenström Macroglobulinemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, 547-556.	0.2	6
12	High frequency of central nervous system involvement in transformed Waldenström macroglobulinemia. <i>Blood Advances</i> , 2022, 6, 3655-3658.	2.5	4
13	A new role for the SRC family kinase HCK as a driver of SYK activation in MYD88 mutated lymphomas. <i>Blood Advances</i> , 2022, 6, 3332-3338.	2.5	4
14	An international analysis evaluating frontline bendamustine with rituximab in extranodal marginal zone lymphoma. <i>Blood Advances</i> , 2022, 6, 2035-2044.	2.5	12
15	When a Monoclonal Gammopathy Is Not Multiple Myeloma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2022, 42, 655-664.	1.8	2
16	Epidemiology of chronic lymphocytic leukemia in Chilean and Amerindian population in Chile. <i>Leukemia and Lymphoma</i> , 2022, 63, 1137-1143.	0.6	2
17	Zanubrutinib for the treatment of adults with Waldenström macroglobulinemia. <i>Expert Review of Anticancer Therapy</i> , 2022, , .	1.1	3
18	Daratumumab with ifosfamide, carboplatin and etoposide for the treatment of relapsed plasmablastic lymphoma. <i>British Journal of Haematology</i> , 2022, 198, .	1.2	7

#	ARTICLE	IF	CITATIONS
19	<sc>EBV</sc>-positive diffuse large B-cell lymphoma, not otherwise specified: 2022 update on diagnosis, risk-stratification, and management. American Journal of Hematology, 2022, 97, 951-965.	2.0	26
20	Bone marrow aspiration in a patient with systemic microsporidium. Clinical Case Reports (discontinued), 2022, 10, .	0.2	1
21	ASPEN: Long-term follow-up results of a phase 3 randomized trial of zanubrutinib (ZANU) versus ibrutinib (IBR) in patients with Waldenström macroglobulinemia (WM).. Journal of Clinical Oncology, 2022, 40, 7521-7521.	0.8	14
22	Bendamustine rituximab (BR) versus ibrutinib (ibr) as primary therapy for Waldenström macroglobulinemia (WM): An international collaborative study.. Journal of Clinical Oncology, 2022, 40, 7566-7566.	0.8	9
23	A phase 2 expanded access study of zanubrutinib (ZANU) in patients (pts) with Waldenström Macroglobulinemia (WM).. Journal of Clinical Oncology, 2022, 40, e19522-e19522.	0.8	1
24	A pilot study on dasatinib in patients with Waldenström macroglobulinemia progressing on ibrutinib. EJHaem, 2022, 3, 927-929.	0.4	1
25	Partial response or better at six months is prognostic of superior progression-free survival in Waldenström macroglobulinaemia patients treated with ibrutinib. British Journal of Haematology, 2021, 192, 542-550.	1.2	8
26	Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With Waldenström Macroglobulinemia. Journal of Clinical Oncology, 2021, 39, 565-575.	0.8	98
27	Clinical application of genomics in Waldenström macroglobulinemia. Leukemia and Lymphoma, 2021, 62, 1805-1815.	0.6	3
28	Clinical, inflammatory and immunohistochemical features in a cohort of Peruvian patients with diffuse large B-cell lymphoma. Leukemia Research, 2021, 102, 106513.	0.4	1
29	Reducing treatment toxicity in Waldenström macroglobulinemia. Expert Opinion on Drug Safety, 2021, 20, 1-8.	1.0	2
30	The evaluation and management of monoclonal gammopathy of renal significance and monoclonal gammopathy of neurological significance. American Journal of Hematology, 2021, 96, 846-853.	2.0	16
31	Bone marrow involvement and subclonal diversity impairs detection of mutated <i>CXCR4</i> by diagnostic next-generation sequencing in Waldenström macroglobulinaemia. British Journal of Haematology, 2021, 194, 730-733.	1.2	16
32	Cell-free <sc>DNA</sc> analysis for detection of <sc><i>MYD88</i>^{L265P}</sc> and <sc><i>CXCR4</i>^{S338X}</sc> mutations in <sc>W</sc>-aldenström macroglobulinemia. American Journal of Hematology, 2021, 96, E250-E253.	2.0	8
33	Prognostic value of disease risk score versus gait speed in older adults with lymphoma. Leukemia and Lymphoma, 2021, 62, 1-8.	0.6	0
34	The HCK/BTK inhibitor KIN-8194 is active in MYD88-driven lymphomas and overcomes mutated BTKCys481 ibrutinib resistance. Blood, 2021, 138, 1966-1979.	0.6	16
35	Anaplastic lymphoma kinase-positive large B-cell lymphoma (ALK+LBCL): a systematic review of clinicopathological features and management. Leukemia and Lymphoma, 2021, 62, 2845-2853.	0.6	8
36	Real-World Data on Adult T-Cell Leukemia/Lymphoma in Latin America: A Study From the Grupo de Estudio Latinoamericano de Linfoproliferativos. JCO Global Oncology, 2021, 7, 1151-1166.	0.8	15

#	ARTICLE	IF	CITATIONS
37	Effect of ibrutinib treatment on hemolytic anemia and acrocyanosis in cold agglutinin disease/cold agglutinin syndrome. <i>Blood</i> , 2021, 138, 2002-2005.	0.6	27
38	Phase 1 study of ibrutinib and the CXCR4 antagonist ulocuplumab in CXCR4-mutated Waldenström macroglobulinemia. <i>Blood</i> , 2021, 138, 1535-1539.	0.6	32
39	Diagnostic Next-generation Sequencing Frequently Fails to Detect MYD88L265P in Waldenström Macroglobulinemia. <i>HemaSphere</i> , 2021, 5, e624.	1.2	15
40	How to Sequence Therapies in Waldenström Macroglobulinemia. <i>Current Treatment Options in Oncology</i> , 2021, 22, 92.	1.3	5
41	Complete response to pembrolizumab and radiation in a patient with <sc>HIV</sc>-negative, <sc>EBV</sc>-positive plasmablastic lymphoma. <i>American Journal of Hematology</i> , 2021, 96, E390-E392.	2.0	5
42	Plasmablastic lymphoma transformation in a patient with Waldenström macroglobulinemia treated with ibrutinib. <i>British Journal of Haematology</i> , 2021, 195, 466-468.	1.2	2
43	Novel Agents for Waldenström Macroglobulinemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S34-S35.	0.2	0
44	Tailoring Therapy in Waldenström Macroglobulinemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S59-S60.	0.2	0
45	A prognostic index predicting survival in transformed Waldenström macroglobulinemia. <i>Haematologica</i> , 2021, 106, 2940-2946.	1.7	11
46	Special Issues in Pregnancy. , 2020, , 882-893.e3.		0
47	HOLA! from Latin America to the myeloma world. <i>British Journal of Haematology</i> , 2020, 188, 349-350.	1.2	1
48	Deepening of response after completing rituximab-containing therapy in patients with Waldenström macroglobulinemia. <i>American Journal of Hematology</i> , 2020, 95, 372-378.	2.0	6
49	Outcomes of bendamustine-or cyclophosphamide-based first-line chemotherapy in older patients with indolent B-cell lymphoma. <i>American Journal of Hematology</i> , 2020, 95, 354-361.	2.0	19
50	Consensus Statement on the Management of Waldenström Macroglobulinemia Patients During the COVID-19 Pandemic. <i>HemaSphere</i> , 2020, 4, e433.	1.2	11
51	Consensus treatment recommendations from the tenth International Workshop for Waldenström Macroglobulinaemia. <i>Lancet Haematology</i> , 2020, 7, e827-e837.	2.2	96
52	Comparative genomics of CXCR4MUT and CXCR4WT single cells in Waldenström's macroglobulinemia. <i>Blood Advances</i> , 2020, 4, 4550-4553.	2.5	3
53	Primary refractory multiple myeloma: a real-world experience with 85 cases. <i>Leukemia and Lymphoma</i> , 2020, 61, 2868-2875.	0.6	6
54	Response and Survival Outcomes to Ibrutinib Monotherapy for Patients With Waldenström Macroglobulinemia on and off Clinical Trials. <i>HemaSphere</i> , 2020, 4, e363.	1.2	12

#	ARTICLE	IF	CITATIONS
55	Management of Waldenström macroglobulinemia in 2020. Hematology American Society of Hematology Education Program, 2020, 2020, 372-379.	0.9	24
56	A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study. Blood, 2020, 136, 2038-2050.	0.6	281
57	Ixazomib, dexamethasone, and rituximab in treatment-naive patients with Waldenström macroglobulinemia: long-term follow-up. Blood Advances, 2020, 4, 3952-3959.	2.5	35
58	Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: a substudy of the phase 3 ASPEN trial. Blood Advances, 2020, 4, 6009-6018.	2.5	57
59	A Multi-Institutional Validation of the Prognostic Value of the Neutrophil-to-Lymphocyte Ratio in Patients With Diffuse Large B-Cell Lymphoma: A Study From The Latin American Group of Lymphoproliferative Disorders (GELL). Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 637-646.	0.2	3
60	Clinicopathologic characteristics and survival of patients with primary effusion lymphoma. Leukemia and Lymphoma, 2020, 61, 2093-2102.	0.6	17
61	The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19 infected patients. Blood, 2020, 135, 1912-1915.	0.6	253
62	A multicenter retrospective study of 223 patients with t(14;16) in multiple myeloma. American Journal of Hematology, 2020, 95, 503-509.	2.0	11
63	EBV positive diffuse large B cell lymphoma, not otherwise specified: 2020 update on diagnosis, risk stratification and management. American Journal of Hematology, 2020, 95, 435-445.	2.0	35
64	Genomic Landscape of Waldenström Macroglobulinemia and Its Impact on Treatment Strategies. Journal of Clinical Oncology, 2020, 38, 1198-1208.	0.8	103
65	Genomic evolution of ibrutinib resistant clones in Waldenström macroglobulinaemia. British Journal of Haematology, 2020, 189, 1165-1170.	1.2	23
66	CXCR4 mutational status does not impact outcomes in patients with Waldenström macroglobulinemia treated with proteasome inhibitors. American Journal of Hematology, 2020, 95, E95-E98.	2.0	12
67	A matched case-control study comparing features, treatment and outcomes between patients with non-IgM lymphoplasmacytic lymphoma and Waldenström macroglobulinemia. Leukemia and Lymphoma, 2020, 61, 1388-1394.	0.6	9
68	SYK is activated by mutated MYD88 and drives pro-survival signaling in MYD88 driven B-cell lymphomas. Blood Cancer Journal, 2020, 10, 12.	2.8	34
69	Different MAF translocations confer similar prognosis in newly diagnosed multiple myeloma patients. Leukemia and Lymphoma, 2020, 61, 1885-1893.	0.6	3
70	Expression of the prosurvival kinase HCK requires PAX5 and mutated MYD88 signaling in MYD88-driven B-cell lymphomas. Blood Advances, 2020, 4, 141-153.	2.5	13
71	Epidemiology, Clinical Features, and Outcome of HTLV-1-Related Adult T-Cell Leukemia/Lymphoma in Latin America: A Study from the Latin American Group of Lymphoproliferative Disorders (GELL). Blood, 2020, 136, 18-21.	0.6	2
72	Updated results of the ASPEN trial from a cohort of patients with MYD88 wild-type (MYD88 ^{WT}) Waldenström macroglobulinemia (WM).. Journal of Clinical Oncology, 2020, 38, e20056-e20056.	0.8	4

#	ARTICLE	IF	CITATIONS
73	Plasma Cell Leukemia – Facts and Controversies: More Questions than Answers?. Clinical Hematology International, 2020, 2, 133.	0.7	5
74	Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 1685-1717.	2.3	138
75	Plasmablastic Lymphoma and Primary Effusion Lymphoma. , 2020, , 101-118.		0
76	Novel Therapeutics in the Management of Waldenström Macroglobulinemia. , 2020, , 15-26.		0
77	Linfoma/Leucemia T del adulto: Entidad prevalente en Sudamérica. Revista De La Facultad De Medicina Humana, 2020, 20, 12-13.	0.1	0
78	Multicenter phase 2 study of daratumumab monotherapy in patients with previously treated Waldenström macroglobulinemia. Blood Advances, 2020, 4, 5089-5092.	2.5	5
79	Outcomes of Patients with Limited-Stage Plasmablastic Lymphoma. Blood, 2020, 136, 15-16.	0.6	0
80	Follicular Lymphoma in Latin America: Real-World Experience from 763 Patients. Blood, 2020, 136, 12-13.	0.6	1
81	Multiple myeloma in patients up to 30 years of age: a multicenter retrospective study of 52 cases. Leukemia and Lymphoma, 2019, 60, 471-476.	0.6	13
82	Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients. Leukemia and Lymphoma, 2019, 60, 118-123.	0.6	23
83	CXCR4 mutations affect presentation and outcomes in patients with Waldenström macroglobulinemia: A systematic review. Expert Review of Hematology, 2019, 12, 873-881.	1.0	29
84	How we manage Bing-Neel syndrome. British Journal of Haematology, 2019, 187, 277-285.	1.2	45
85	CXCR4 mutation subtypes impact response and survival outcomes in patients with Waldenström macroglobulinaemia treated with ibrutinib. British Journal of Haematology, 2019, 187, 356-363.	1.2	73
86	Hematogenous extramedullary relapse in multiple myeloma – a multicenter retrospective study in 127 patients. American Journal of Hematology, 2019, 94, 1132-1140.	2.0	24
87	High Red Cell Distribution Width is an Adverse Predictive and Prognostic Factor in Patients With Diffuse Large B-Cell Lymphoma Treated With Chemoimmunotherapy. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e551-e557.	0.2	9
88	Lymphoplasmacytic Lymphoma and Marginal Zone Lymphoma. Hematology/Oncology Clinics of North America, 2019, 33, 639-656.	0.9	12
89	Reply to F.D. Leonard. Journal of Clinical Oncology, 2019, 37, 2701-2702.	0.8	0
90	What is new in the treatment of Waldenstrom macroglobulinemia?. Leukemia, 2019, 33, 2555-2562.	3.3	19

#	ARTICLE	IF	CITATIONS
91	Progression Risk Stratification of Asymptomatic Waldenström Macroglobulinemia. <i>Journal of Clinical Oncology</i> , 2019, 37, 1403-1411.	0.8	65
92	CXCR4 S338X clonality is an important determinant of ibrutinib outcomes in patients with Waldenström macroglobulinemia. <i>Blood Advances</i> , 2019, 3, 2800-2803.	2.5	27
93	Genomic landscape of Waldenström's macroglobulinemia. <i>HemaSphere</i> , 2019, 3, 58-61.	1.2	1
94	Multicenter prospective phase II study of venetoclax in patients with previously treated Waldenström macroglobulinemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e39-e40.	0.2	9
95	<i>TP53</i> mutations are associated with mutated <i>MYD88</i> and <i>CXCR4</i> , and confer an adverse outcome in Waldenström macroglobulinemia. <i>British Journal of Haematology</i> , 2019, 184, 242-245.	1.2	33
96	Long survival in patients with Waldenström macroglobulinemia diagnosed at a young age. <i>British Journal of Haematology</i> , 2019, 185, 799-802.	1.2	4
97	Outcomes of secondary solid tumor malignancies among patients with myeloma: A population-based study. <i>Cancer</i> , 2019, 125, 550-558.	2.0	6
98	Low risk of <i>Pneumocystis jirovecii</i> pneumonia and invasive aspergillosis in patients with Waldenström macroglobulinemia on ibrutinib. <i>British Journal of Haematology</i> , 2019, 185, 788-790.	1.2	12
99	Ibrutinib for the treatment of Bing-Neel syndrome: a multicenter study. <i>Blood</i> , 2019, 133, 299-305.	0.6	69
100	Bortezomib plus <i>EPOCH</i> is effective as frontline treatment in patients with plasmablastic lymphoma. <i>British Journal of Haematology</i> , 2019, 184, 679-682.	1.2	55
101	Low levels of von Willebrand markers associate with high serum IgM levels and improve with response to therapy, in patients with Waldenström macroglobulinemia. <i>British Journal of Haematology</i> , 2019, 184, 1011-1014.	1.2	19
102	The neutrophil:lymphocyte ratio is prognostic in patients with early stage aggressive peripheral T cell lymphoma. <i>British Journal of Haematology</i> , 2019, 184, 650-653.	1.2	14
103	Identifying a Simple Clinical Prognostic Model for Aggressive Adult T-Cell Leukemia/Lymphoma in Latin American Population and Its Validation: A Large International Study of the Latin America Working Group for Lymphomas (GELL). <i>Blood</i> , 2019, 134, 4045-4045.	0.6	2
104	CD20-Negative Aggressive Lymphomas. <i>Mechanical Engineering Series</i> , 2019, , 213-226.	0.1	0
105	The impact of the neutrophil:lymphocyte ratio in response and survival of patients with de novo diffuse large B-cell lymphoma. <i>Leukemia Research</i> , 2018, 67, 82-85.	0.4	9
106	Response and survival for primary therapy combination regimens and maintenance rituximab in Waldenström macroglobulinemia. <i>British Journal of Haematology</i> , 2018, 181, 77-85.	1.2	41
107	BTK ^{Cys481Ser} drives ibrutinib resistance via ERK1/2 and protects BTK ^{wild-type} MYD88-mutated cells by a paracrine mechanism. <i>Blood</i> , 2018, 131, 2047-2059.	0.6	61
108	True, true unrelated? Coexistence of Waldenström macroglobulinemia and cardiac transthyretin amyloidosis. <i>Haematologica</i> , 2018, 103, e374-e376.	1.7	6

#	ARTICLE	IF	CITATIONS
109	Prospective Clinical Trial of Ixazomib, Dexamethasone, and Rituximab as Primary Therapy in Waldenström Macroglobulinemia. <i>Clinical Cancer Research</i> , 2018, 24, 3247-3252.	3.2	57
110	Fitting mSMART Into the Current Clinical Management of Waldenström Macroglobulinemia. <i>JAMA Oncology</i> , 2018, 4, 744.	3.4	0
111	Ibrutinib discontinuation in Waldenström macroglobulinemia: Etiologies, outcomes, and IgM rebound. <i>American Journal of Hematology</i> , 2018, 93, 511-517.	2.0	61
112	Prognostic indicators in primary plasma cell leukaemia: a multicentre retrospective study of 117 patients. <i>British Journal of Haematology</i> , 2018, 180, 831-839.	1.2	41
113	Ibrutinib withdrawal symptoms in patients with Waldenström macroglobulinemia. <i>Haematologica</i> , 2018, 103, e307-e310.	1.7	45
114	<i>MYD88</i> mutated and wild-type Waldenströmâ€™s Macroglobulinemia: characterization of chromosome 6q gene losses and their mutual exclusivity with mutations in <i>CXCR4</i>. <i>Haematologica</i> , 2018, 103, e408-e411.	1.7	30
115	<i>MYD88</i> mutations can be used to identify malignant pleural effusions in Waldenström macroglobulinaemia. <i>British Journal of Haematology</i> , 2018, 180, 578-581.	1.2	19
116	Response and survival benefit with chemoimmunotherapy in Epsteinâ€Barr virusâ€positive diffuse large Bâ€cell lymphoma. <i>Hematological Oncology</i> , 2018, 36, 93-97.	0.8	22
117	Late infections and secondary malignancies after bendamustine/rituximab or RCHOP/RCVP chemotherapy for Bâ€cell lymphomas. <i>American Journal of Hematology</i> , 2018, 93, E1-E3.	2.0	15
118	Survival of patients with CD20-negative variants of large B-cell lymphoma: an analysis of the National Cancer Data Base. <i>Leukemia and Lymphoma</i> , 2018, 59, 1375-1383.	0.6	27
119	<i>MYD88</i> wildâ€type Waldenstrom Macroglobulinaemia: differential diagnosis, risk of histological transformation, andâ€overall survival. <i>British Journal of Haematology</i> , 2018, 180, 374-380.	1.2	83
120	Comparing apples to oranges: A commentary on the <sc>M</sc>ayo study of <sc>MYD88</sc> significance in <sc>W</sc>aldenstrom's macroglobulinemia.. <i>American Journal of Hematology</i> , 2018, 93, E69-E71.	2.0	1
121	Primary cutaneous plasmablastic lymphoma in an immunocompetent patient: is it associated with an indolent course?. <i>Leukemia and Lymphoma</i> , 2018, 59, 1753-1755.	0.6	5
122	Ibrutinib Monotherapy in Symptomatic, Treatment-Naïve Patients With Waldenström Macroglobulinemia. <i>Journal of Clinical Oncology</i> , 2018, 36, 2755-2761.	0.8	142
123	1130. Low Risk of Pneumocystis jiroveci Pneumonia in Patients With Waldenstromâ€™s Macroglobulinemia on Ibrutinib. <i>Open Forum Infectious Diseases</i> , 2018, 5, S338-S339.	0.4	0
124	Profiling of circulating exosomal miRNAs in patients with Waldenström Macroglobulinemia. <i>PLoS ONE</i> , 2018, 13, e0204589.	1.1	17
125	Bortezomib overcomes the negative impact of CXCR4 mutations on survival of Waldenstrom macroglobulinemia patients. <i>Blood</i> , 2018, 132, 2608-2612.	0.6	29
126	Waldenström Macroglobulinemia: Lessons Learned from Basic and Clinical Research. <i>Hematology/Oncology Clinics of North America</i> , 2018, 32, xiii-xiv.	0.9	0

#	ARTICLE	IF	CITATIONS
127	Viral lymphomagenesis: beyond the usual suspects. British Journal of Haematology, 2018, 182, 617-618.	1.2	0
128	Impact of ibrutinib dose intensity on patient outcomes in previously treated Waldenström macroglobulinemia. Haematologica, 2018, 103, e466-e468.	1.7	18
129	Spotting the elusive Siberian tiger: Complete response to ibrutinib in a patient with Waldenström macroglobulinemia. American Journal of Hematology, 2018, 93, E201.	2.0	1
130	The real world of Waldenström's macroglobulinaemia. Lancet Haematology, the, 2018, 5, e275-e276.	2.2	2
131	Initial Evaluation of the Patient with Waldenström Macroglobulinemia. Hematology/Oncology Clinics of North America, 2018, 32, 811-820.	0.9	16
132	Genomic Landscape of Waldenström Macroglobulinemia. Hematology/Oncology Clinics of North America, 2018, 32, 745-752.	0.9	16
133	Monoclonal Antibodies for Waldenström Macroglobulinemia. Hematology/Oncology Clinics of North America, 2018, 32, 841-852.	0.9	0
134	Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma. , 2018, , 1419-1431.e5.		0
135	EBV-positive diffuse large B-cell lymphoma, not otherwise specified: 2018 update on diagnosis, risk stratification and management. American Journal of Hematology, 2018, 93, 953-962.	2.0	75
136	Clinical characteristics and treatment outcomes in IgE multiple myeloma: A case-control study. American Journal of Hematology, 2018, 93, E238-E241.	2.0	6
137	Multicenter Prospective Phase II Study of Venetoclax in Patients with Previously Treated Waldenström Macroglobulinemia. Blood, 2018, 132, 2888-2888.	0.6	22
138	Non-IgM Secreting Lymphoplasmacytic Lymphoma - Experience of a Reference Center for Waldenström Macroglobulinemia. Blood, 2018, 132, 2886-2886.	0.6	9
139	A Novel HCK Inhibitor Kin-8193 Blocks BTK Activity in BTKCys481 Mutated Ibrutinib Resistant B-Cell Lymphomas Driven By Mutated MYD88. Blood, 2018, 132, 40-40.	0.6	9
140	Alternative Mutations and Isoform Dysregulation in MYD88 in Waldenström's Macroglobulinemia. Blood, 2018, 132, 1566-1566.	0.6	4
141	Insights into the genomic landscape of MYD88 wild-type Waldenström macroglobulinemia. Blood Advances, 2018, 2, 2937-2946.	2.5	72
142	Acquired mutations associated with ibrutinib resistance in Waldenström macroglobulinemia. Blood, 2017, 129, 2519-2525.	0.6	115
143	Investigation and management of IgM and Waldenström-associated peripheral neuropathies: recommendations from the IWWM-8 consensus panel. British Journal of Haematology, 2017, 176, 728-742.	1.2	58
144	Serum IgM level as predictor of symptomatic hyperviscosity in patients with Waldenström macroglobulinaemia. British Journal of Haematology, 2017, 177, 717-725.	1.2	58

#	ARTICLE	IF	CITATIONS
145	Novel approaches to targeting MYD88 in Waldenström's macroglobulinemia. Expert Review of Hematology, 2017, 10, 739-744.	1.0	6
146	IgM myeloma: A multicenter retrospective study of 134 patients. American Journal of Hematology, 2017, 92, 746-751.	2.0	45
147	Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial. Lancet Oncology, The, 2017, 18, 241-250.	5.1	212
148	Guideline for the diagnosis, treatment and response criteria for Bing-Neel syndrome. Haematologica, 2017, 102, 43-51.	1.7	112
149	Bortezomib in plasmablastic lymphoma: A glimpse of hope for a hard-to-treat disease. Leukemia Research, 2017, 62, 12-16.	0.4	32
150	Comparative outcomes of immunochemotherapy regimens in Waldenström's macroglobulinaemia. British Journal of Haematology, 2017, 179, 106-115.	1.2	14
151	Similar survival outcomes in patients with biclonal versus monoclonal myeloma: a multi-institutional matched case-control study. Annals of Hematology, 2017, 96, 1693-1698.	0.8	7
152	CXCL13 levels are elevated in patients with Waldenström's macroglobulinemia, and are predictive of major response to ibrutinib. Haematologica, 2017, 102, e452-e455.	1.7	22
153	To select or not to select? The role of B-cell selection in determining the MYD88 mutation status in Waldenström's Macroglobulinaemia. British Journal of Haematology, 2017, 176, 822-824.	1.2	22
154	Targeting Myddosome Assembly in Waldenström's Macroglobulinaemia. British Journal of Haematology, 2017, 177, 808-813.	1.2	13
155	Ibrutinib penetrates the blood brain barrier and shows efficacy in the therapy of Bing Neel syndrome. British Journal of Haematology, 2017, 179, 339-341.	1.2	56
156	Secondary malignancies in patients with multiple myeloma, Waldenström's macroglobulinemia and monoclonal gammopathy of undetermined significance. Leukemia and Lymphoma, 2017, 58, 773-780.	0.6	24
157	Idelalisib in Waldenström's macroglobulinemia: high incidence of hepatotoxicity. Leukemia and Lymphoma, 2017, 58, 1002-1004.	0.6	31
158	Signal Inhibitors in Waldenström's Macroglobulinemia. , 2017, , 327-334.		0
159	Immunomodulatory Agents and Proteasome Inhibitors in Waldenström's Macroglobulinemia. , 2017, , 335-343.		0
160	Genetic and Signaling Abnormalities in Waldenström's Macroglobulinemia. , 2017, , 53-65.		1
161	Prospective, Multicenter Clinical Trial of Everolimus as Primary Therapy in Waldenström's Macroglobulinemia (WMCTG 09-214). Clinical Cancer Research, 2017, 23, 2400-2404.	3.2	23
162	Toward personalized treatment in Waldenström's macroglobulinemia. Hematology American Society of Hematology Education Program, 2017, 2017, 365-370.	0.9	7

#	ARTICLE	IF	CITATIONS
163	Genomics, Signaling, and Treatment of Waldenström Macroglobulinemia. <i>Journal of Clinical Oncology</i> , 2017, 35, 994-1001.	0.8	76
164	What should be the goal of therapy for Waldenström macroglobulinemia patients? Complete response should be the goal of therapy. <i>Blood Advances</i> , 2017, 1, 2486-2490.	2.5	5
165	12. Waldenström's macroglobulinemia. , 2016, , 229-244.		0
166	Inhibition of the Bruton Tyrosine Kinase Pathway in B-Cell Lymphoproliferative Disorders. <i>Cancer Journal (Sudbury, Mass)</i> , 2016, 22, 34-39.	1.0	25
167	Outcomes of HIV-associated Hodgkin lymphoma in the era of antiretroviral therapy. <i>Aids</i> , 2016, 30, 787-796.	1.0	29
168	Central nervous system involvement by Waldenström macroglobulinaemia (Bing-Neel syndrome): a multi-institutional retrospective study. <i>British Journal of Haematology</i> , 2016, 172, 709-715.	1.2	87
169	Human immunodeficiency virus-associated lymphomas in the antiretroviral therapy era: Analysis of the National Cancer Data Base. <i>Cancer</i> , 2016, 122, 2689-2697.	2.0	43
170	Relationship between obesity and clinical outcome in adults with acute myeloid leukemia: A pooled analysis from four CALGB (alliance) clinical trials. <i>American Journal of Hematology</i> , 2016, 91, 199-204.	2.0	44
171	Transformation of a previously diagnosed diffuse large B-cell lymphoma to plasmablastic lymphoma. <i>American Journal of Hematology</i> , 2016, 91, E324.	2.0	5
172	Central nervous system involvement by multiple myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice. <i>American Journal of Hematology</i> , 2016, 91, 575-580.	2.0	83
173	Risk factors for progression from smoldering into active myeloma: additional insights from a population-based study. <i>European Journal of Haematology</i> , 2016, 97, 217-218.	1.1	0
174	Risk Factors for Early Death After Rituximab-Based Immunochemotherapy in Older Patients With Diffuse Large B-Cell Lymphoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 1121-1129.	2.3	18
175	Survival Claims From Observational Data on Cancer Therapy. <i>Journal of Clinical Oncology</i> , 2016, 34, 1425-1427.	0.8	3
176	Exome sequencing reveals recurrent germ line variants in patients with familial Waldenström macroglobulinemia. <i>Blood</i> , 2016, 127, 2598-2606.	0.6	22
177	Transcriptome sequencing reveals a profile that corresponds to genomic variants in Waldenström macroglobulinemia. <i>Blood</i> , 2016, 128, 827-838.	0.6	91
178	Treatment recommendations from the Eighth International Workshop on Waldenström's Macroglobulinemia. <i>Blood</i> , 2016, 128, 1321-1328.	0.6	161
179	Characteristics and outcomes of patients with multiple myeloma aged 21-40 years versus 41-60 years: a multi-institutional case-control study. <i>British Journal of Haematology</i> , 2016, 175, 884-891.	1.2	21
180	All the soarings of my mind begin in my blood: central nervous system complication of Waldenström macroglobulinemia. <i>American Journal of Hematology</i> , 2016, 91, 1057-1060.	2.0	0

#	ARTICLE	IF	CITATIONS
181	Future therapeutic options for patients with Waldenström macroglobulinemia. Best Practice and Research in Clinical Haematology, 2016, 29, 206-215.	0.7	4
182	Evolution of Management and Outcomes in Waldenström Macroglobulinemia: A Population-Based Analysis. Oncologist, 2016, 21, 1377-1386.	1.9	36
183	Histological transformation to diffuse large B-cell lymphoma in patients with Waldenström macroglobulinemia. American Journal of Hematology, 2016, 91, 1032-1035.	2.0	53
184	EBV-positive diffuse large B-cell lymphoma of the elderly: 2016 update on diagnosis, risk stratification, and management. American Journal of Hematology, 2016, 91, 529-537.	2.0	74
185	Rituximab intolerance in patients with Waldenström macroglobulinaemia. British Journal of Haematology, 2016, 174, 645-648.	1.2	34
186	Renal disease related to Waldenström macroglobulinaemia: incidence, pathology and clinical outcomes. British Journal of Haematology, 2016, 175, 623-630.	1.2	68
187	The occurrence of hyponatremia and its importance as a prognostic factor in a cross-section of cancer patients. BMC Cancer, 2016, 16, 564.	1.1	63
188	HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib. Blood, 2016, 127, 3237-3252.	0.6	93
189	Recommendations for the diagnosis and initial evaluation of patients with Waldenström Macroglobulinaemia: A Task Force from the 8th International Workshop on Waldenström Macroglobulinaemia. British Journal of Haematology, 2016, 175, 77-86.	1.2	61
190	Ibrutinib in Waldenström macroglobulinemia: latest evidence and clinical experience. Therapeutic Advances in Hematology, 2016, 7, 179-186.	1.1	28
191	Plasma Cell Disorders. Primary Care - Clinics in Office Practice, 2016, 43, 677-691.	0.7	22
192	Cancer-Related Hyponatremia: Enhancing Recognition and Improving Management. Clinical Lung Cancer, 2016, 17, e29.	1.1	1
193	Atrial fibrillation associated with ibrutinib in Waldenström macroglobulinemia. American Journal of Hematology, 2016, 91, E312-3.	2.0	52
194	Clonal architecture of CXCR4 and WHIM-like mutations in Waldenström Macroglobulinaemia. British Journal of Haematology, 2016, 172, 735-744.	1.2	122
195	Response to ibrutinib in a patient with IgG lymphoplasmacytic lymphoma carrying the MYD88 L265P gene mutation. Leukemia and Lymphoma, 2016, 57, 2699-2701.	0.6	4
196	Cutaneous involvement in multiple myeloma: a multi-institutional retrospective study of 53 patients. Leukemia and Lymphoma, 2016, 57, 2071-2076.	0.6	30
197	The neutrophil-to-lymphocyte ratio is an independent prognostic factor in patients with peripheral T-cell lymphoma, unspecified. Leukemia and Lymphoma, 2016, 57, 58-62.	0.6	34
198	The BCL2 antagonist ABT199 triggers apoptosis, and augments ibrutinib and idelalisib mediated cytotoxicity in CXCR4 ^{hi} Wildtype and CXCR4 ^{hi} WHIM ^{hi} mutated Waldenström macroglobulinaemia cells. British Journal of Haematology, 2015, 170, 134-138.	1.2	63

#	ARTICLE	IF	CITATIONS
199	Bing-Neel syndrome: a rare complication of Waldenström macroglobulinemia. <i>Blood</i> , 2015, 126, 1390-1390.	0.6	2
200	Incidence of secondary malignancies among patients with Waldenström macroglobulinemia: An analysis of the SEER database. <i>Cancer</i> , 2015, 121, 2230-2236.	2.0	33
201	Survival outcomes of secondary cancers in patients with Waldenström macroglobulinemia: An analysis of the SEER database. <i>American Journal of Hematology</i> , 2015, 90, 696-701.	2.0	20
202	Biology, Prognosis, and Therapy of Waldenström Macroglobulinemia. <i>Cancer Treatment and Research</i> , 2015, 165, 177-195.	0.2	17
203	CD20-negative diffuse large B-cell lymphomas: biology and emerging therapeutic options. <i>Expert Review of Hematology</i> , 2015, 8, 343-354.	1.0	31
204	Prognostic factors for advanced-stage human immunodeficiency virus-associated classical Hodgkin lymphoma treated with doxorubicin, bleomycin, vinblastine, and dacarbazine plus combined antiretroviral therapy: A multi-institutional retrospective study. <i>Cancer</i> , 2015, 121, 423-431.	2.0	34
205	Bortezomib in combination with infusional dose-adjusted EPOCH for the treatment of plasmablastic lymphoma. <i>British Journal of Haematology</i> , 2015, 169, 352-355.	1.2	71
206	Treatment Selection and Outcomes in Early-Stage Classical Hodgkin Lymphoma: Analysis of the National Cancer Data Base. <i>Journal of Clinical Oncology</i> , 2015, 33, 625-633.	0.8	91
207	Cyclophosphamide, bortezomib, and dexamethasone combination in Waldenström macroglobulinemia. <i>American Journal of Hematology</i> , 2015, 90, E122-3.	2.0	13
208	Extramedullary Waldenström macroglobulinemia. <i>American Journal of Hematology</i> , 2015, 90, 100-104.	2.0	47
209	Validation of clinical prognostic indices for diffuse large B-cell lymphoma in the National Cancer Data Base. <i>Cancer Causes and Control</i> , 2015, 26, 1163-1172.	0.8	18
210	The biology and treatment of plasmablastic lymphoma. <i>Blood</i> , 2015, 125, 2323-2330.	0.6	355
211	Ibrutinib in Previously Treated Waldenström's Macroglobulinemia. <i>New England Journal of Medicine</i> , 2015, 372, 1430-1440.	13.9	810
212	The WHIM-like CXCR4S338X somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenström's Macroglobulinemia. <i>Leukemia</i> , 2015, 29, 169-176.	3.3	180
213	Potential for improved survival with intensification of daunorubicin based induction chemotherapy in acute myeloid leukemia patients who do not receive transplant: A multicenter retrospective study. <i>Leukemia Research</i> , 2015, 39, 812-817.	0.4	3
214	CXCR4 WHIM-like frameshift and nonsense mutations promote ibrutinib resistance but do not supplant MYD88 L265P-directed survival signalling in Waldenström macroglobulinemia cells. <i>British Journal of Haematology</i> , 2015, 168, 701-707.	1.2	95
215	Overall survival and competing risks of death in patients with Waldenström macroglobulinemia: an analysis of the Surveillance, Epidemiology and End Results database. <i>British Journal of Haematology</i> , 2015, 169, 81-89.	1.2	110
216	Phase I/II trial of everolimus in combination with bortezomib and rituximab (RVR) in relapsed/refractory Waldenström macroglobulinemia. <i>Leukemia</i> , 2015, 29, 2338-2346.	3.3	34

#	ARTICLE	IF	CITATIONS
217	Plasma fatty acid profile in multiple myeloma patients. <i>Leukemia Research</i> , 2015, 39, 400-405.	0.4	35
218	CD20-negative diffuse large B-cell lymphoma presenting with lactic acidosis. <i>American Journal of Hematology</i> , 2015, 90, E49-50.	2.0	10
219	Large B-cell lymphoma arising in cardiac myxoma or intracardiac fibrinous mass: a localized lymphoma usually associated with Epstein-Barr virus?. <i>Cardiovascular Pathology</i> , 2015, 24, 60-64.	0.7	35
220	Next Generation Sequencing Identifies a Distinct Transcriptional Profile, Including Isoform Dysregulation That Segue with Genomic Alterations in Waldenstrom's Macroglobulinemia. <i>Blood</i> , 2015, 126, 128-128.	0.6	1
221	Long-Term Outcome of a Prospective Study of Bortezomib, Dexamethasone and Rituximab (BDR) in Previously Untreated, Symptomatic Patients with Waldenstrom's Macroglobulinemia. <i>Blood</i> , 2015, 126, 1833-1833.	0.6	23
222	Ibrutinib Therapy in Rituximab-Refractory Patients with Waldenstrom's Macroglobulinemia: Initial Results from an International, Multicenter, Open-Label Phase 3 Substudy (iNNOVATETM). <i>Blood</i> , 2015, 126, 2745-2745.	0.6	12
223	Risk Factors for Early Death after Immunochemotherapy in Older Patients with Diffuse Large B-Cell Lymphoma (DLBCL). <i>Blood</i> , 2015, 126, 3914-3914.	0.6	1
224	Defining the Incidence, Pathology and Clinical Outcomes of Kidney Disease Related to Waldenstrom's Macroglobulinemia and IgM MGUS. <i>Blood</i> , 2015, 126, 3926-3926.	0.6	2
225	Targeting IRAK1/IRAK4 Signaling in Waldenstrom's Macroglobulinemia. <i>Blood</i> , 2015, 126, 4004-4004.	0.6	11
226	The Role of Day 14 Bone Marrow Analysis in Determining Leukemia Free Survival and Overall Survival. <i>Blood</i> , 2015, 126, 4974-4974.	0.6	3
227	HCK Is a Highly Relevant Target of Ibrutinib in MYD88 Mutated Waldenstrom's Macroglobulinemia and Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2015, 126, 705-705.	0.6	3
228	Whole Genome and Transcriptome Analysis of Waldenstrom's Cell Lines Show Preservation of Many Important Genomic Features of Primary Disease, and Identify a Non-L265P Mutation in MYD88. <i>Blood</i> , 2015, 126, 2665-2665.	0.6	3
229	Prognosis of HIV-Associated Hodgkin Lymphoma in the Antiretroviral Therapy Era: Analysis of the National Cancer Data Base (NCDB). <i>Blood</i> , 2015, 126, 3861-3861.	0.6	0
230	High Rates of HTLV-1 Seropositivity in Patients with EBV-Positive Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2015, 126, 5049-5049.	0.6	0
231	The Neutrophil-Lymphocyte Ratio Is a Prognostic Marker in Patients with EBV-Positive Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2015, 126, 5047-5047.	0.6	0
232	CURRENT KNOWLEDGE ON HIV-ASSOCIATED PLASMABLASTIC LYMPHOMA. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2014, 6, e2014064.	0.5	49
233	Isotype-specific inhibition of the phosphatidylinositol-3-kinase pathway in hematologic malignancies. <i>OncoTargets and Therapy</i> , 2014, 7, 333.	1.0	9
234	Primary refractory Hodgkin lymphoma: Limited options and poor survival—but not always. <i>American Journal of Hematology</i> , 2014, 89, 853-857.	2.0	1

#	ARTICLE	IF	CITATIONS
235	Sites of extranodal involvement are prognostic in patients with diffuse large B-cell lymphoma in the rituximab era: An analysis of the Surveillance, Epidemiology and End Results database. <i>American Journal of Hematology</i> , 2014, 89, 310-314.	2.0	120
236	Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy. <i>Annals of Oncology</i> , 2014, 25, 2211-2217.	0.6	126
237	Improving the accuracy in prognosis for Burkitt lymphoma patients. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 125-127.	1.1	6
238	Thalidomide for the treatment of hydroa vacciniforme-like lymphoma: Report of four pediatric cases from Peru. <i>American Journal of Hematology</i> , 2014, 89, 1160-1161.	2.0	20
239	Extranodal Marginal Zone Lymphoma From Ocular Adnexae With Subcutaneous Involvement. <i>American Journal of Dermatopathology</i> , 2014, 36, e189-e193.	0.3	3
240	Ofatumumab as front-line therapy in untreated chronic lymphocytic leukemia. <i>Future Oncology</i> , 2014, 10, 1147-1155.	1.1	9
241	Improved survival with rituximab-based chemoimmunotherapy in older patients with extranodal diffuse large B-cell lymphoma. <i>Leukemia Research</i> , 2014, 38, 866-873.	0.4	20
242	Viral lymphomagenesis: from pathophysiology to the rationale for novel therapies. <i>British Journal of Haematology</i> , 2014, 165, 300-315.	1.2	24
243	Obesity Is Associated With Increased Relative Risk of Diffuse Large B-Cell Lymphoma: A Meta-Analysis of Observational Studies. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, 122-130.	0.2	36
244	Detection of MYD88 L265P in peripheral blood of patients with Waldenström's Macroglobulinemia and IgM monoclonal gammopathy of undetermined significance. <i>Leukemia</i> , 2014, 28, 1698-1704.	3.3	100
245	Hematopoietic Cell Transplantation for Plasmablastic Lymphoma: A Review. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1877-1884.	2.0	71
246	The relation between cigarette smoking and risk of acute myeloid leukemia: An updated meta-analysis of epidemiological studies. <i>American Journal of Hematology</i> , 2014, 89, E125-32.	2.0	89
247	Systemic lupus erythematosus is associated with increased incidence of hematologic malignancies: A meta-analysis of prospective cohort studies. <i>Leukemia Research</i> , 2014, 38, 1067-1071.	0.4	38
248	Breast Implant-Associated Anaplastic Large-Cell Lymphoma: Long-Term Follow-Up of 60 Patients. <i>Journal of Clinical Oncology</i> , 2014, 32, 114-120.	0.8	338
249	Waldenström Macroglobulinemia. <i>Hematology/Oncology Clinics of North America</i> , 2014, 28, 945-970.	0.9	21
250	Erythrocyte membrane fatty acids in multiple myeloma patients. <i>Leukemia Research</i> , 2014, 38, 1260-1265.	0.4	33
251	Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenström's macroglobulinemia. <i>Blood</i> , 2014, 124, 503-510.	0.6	168
252	Survival trends in Waldenström macroglobulinemia: an analysis of the Surveillance, Epidemiology and End Results database. <i>Blood</i> , 2014, 123, 3999-4000.	0.6	91

#	ARTICLE	IF	CITATIONS
253	Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis. <i>Blood</i> , 2014, 124, 2354-2361.	0.6	382
254	Updated Results from a Multicenter, Open-Label, Dose-Escalation Phase 1b/2 Study of Single-Agent Oprozomib in Patients with Waldenström Macroglobulinemia (WM). <i>Blood</i> , 2014, 124, 1715-1715.	0.6	28
255	Special Issues in Pregnancy. , 2014, , 914-925.e3.		0
256	Survival in patients with metastatic prostate cancer in Peru.. <i>Journal of Clinical Oncology</i> , 2014, 32, e16110-e16110.	0.8	0
257	Peripheral T-cell lymphomas (PTCL) in the modern era: Prognosis and impact of therapy in a large U.S. multicenter cohort.. <i>Journal of Clinical Oncology</i> , 2014, 32, e19561-e19561.	0.8	0
258	Cellular immunotherapy for refractory hematological malignancies. <i>Journal of Translational Medicine</i> , 2013, 11, 150.	1.8	28
259	Population-based prognostic factors for survival in patients with Burkitt lymphoma: An analysis from the Surveillance, Epidemiology, and End Results database. <i>Cancer</i> , 2013, 119, 3672-3679.	2.0	55
260	Follicular lymphoma with leukemic phase at diagnosis: A series of seven cases and review of the literature. <i>Leukemia Research</i> , 2013, 37, 1116-1119.	0.4	20
261	Spontaneous regression of chronic lymphocytic leukemia to a monoclonal B-lymphocytosis or to a normal phenotype. <i>Leukemia and Lymphoma</i> , 2013, 54, 1647-1651.	0.6	12
262	Multiple myeloma-induced hyperammonemic encephalopathy: An entity associated with high in-patient mortality. <i>Leukemia Research</i> , 2013, 37, 1229-1232.	0.4	32
263	Hepatitis B infection increases the risk of non-Hodgkin lymphoma: A meta-analysis of observational studies. <i>Leukemia Research</i> , 2013, 37, 1107-1115.	0.4	77
264	Similar outcomes in Asian and Western patients with diffuse large B-cell lymphoma treated with R-CHOP. <i>Leukemia Research</i> , 2013, 37, 386-391.	0.4	6
265	Survival of patients with marginal zone lymphoma. <i>Cancer</i> , 2013, 119, 629-638.	2.0	181
266	Extranodal marginal zone lymphoma of the cranial dura mater: report of three cases and systematic review of the literature. <i>Leukemia and Lymphoma</i> , 2013, 54, 2306-2309.	0.6	8
267	Comparative outcomes of oncologic therapy in gastric extranodal marginal zone (MALT) lymphoma: analysis of the SEER-Medicare database. <i>Annals of Oncology</i> , 2013, 24, 1352-1359.	0.6	29
268	Reply to A. Messori et al.. <i>American Journal of Hematology</i> , 2013, 88, 435-436.	2.0	0
269	Grey Zone Lymphoma, Unclassifiable With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma: Better Results With CHOP-Like Regimens. <i>Blood</i> , 2013, 122, 5105-5105.	0.6	3
270	Impact Of Induction Regimen and Consolidative Stem Cell Transplantation In Patients With Double Hit Lymphoma (DHL): A Large Multicenter Retrospective Analysis. <i>Blood</i> , 2013, 122, 640-640.	0.6	7

#	ARTICLE	IF	CITATIONS
271	Obesity Is An Adverse Prognostic Factor For Overall and Disease-Free Survival In Adult Acute Promyelocytic Leukemia But Not In Acute Myeloid Leukemia: A Pooled Analysis From Four Alliance Prospective Studies. <i>Blood</i> , 2013, 122, 832-832.	0.6	1
272	Prognostic Factors in Peripheral T-Cell Lymphomas. , 2013, , 141-152.		0
273	Prognostic Factors in HIV-Associated Lymphoma. , 2013, , 153-169.		0
274	Combination Of Ofatumumab and Bortezomib In Patients With Indolent B-Cell Lymphomas Who Relapsed >6 Months After Rituximab-Containing Regimen: A Brown University Oncology Research Group Phase II Study. <i>Blood</i> , 2013, 122, 5121-5121.	0.6	0
275	Not All Aggressive Adult T-Cell Leukemia/Lymphoma Subtypes Are Created Equal. <i>Journal of Clinical Oncology</i> , 2012, 30, 3560-3560.	0.8	2
276	Diffuse Large B-Cell Lymphoma in Human T-Lymphotropic Virus Type 1 Carriers. <i>Leukemia Research and Treatment</i> , 2012, 2012, 1-4.	2.0	9
277	Risk factors associated with Clostridium difficile infection in adult oncology patients with a history of recent hospitalization for febrile neutropenia. <i>Leukemia and Lymphoma</i> , 2012, 53, 1617-1619.	0.6	20
278	The girl with the iron tattoo. <i>Virulence</i> , 2012, 3, 599-600.	1.8	5
279	Acute Myeloid Leukemia Evolving from JAK 2-Positive Primary Myelofibrosis and Concomitant CD5-Negative Mantle Cell Lymphoma: A Case Report and Review of the Literature. <i>Case Reports in Hematology</i> , 2012, 2012, 1-6.	0.3	0
280	Peripheral T-cell Lymphoma With a Regulatory T-cell Phenotype. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2012, 20, 196-200.	0.6	7
281	Increased incidence of non-Hodgkin lymphoma, leukemia, and myeloma in patients with diabetes mellitus type 2: a meta-analysis of observational studies. <i>Blood</i> , 2012, 119, 4845-4850.	0.6	177
282	CAL-101: a phosphatidylinositol-3-kinase p110-delta inhibitor for the treatment of lymphoid malignancies. <i>Expert Opinion on Investigational Drugs</i> , 2012, 21, 15-22.	1.9	64
283	Prognosis in primary effusion lymphoma is associated with the number of body cavities involved. <i>Leukemia and Lymphoma</i> , 2012, 53, 2378-2382.	0.6	58
284	Diagnosis and Management of Hyponatremia in Cancer Patients. <i>Oncologist</i> , 2012, 17, 756-765.	1.9	188
285	Cigarette smoking is associated with a small increase in the incidence of non-Hodgkin lymphoma: a meta-analysis of 24 observational studies. <i>Leukemia and Lymphoma</i> , 2012, 53, 1911-1919.	0.6	21
286	Why is My Patient Neutropenic?. <i>Hematology/Oncology Clinics of North America</i> , 2012, 26, 253-266.	0.9	6
287	PCI-32765: a novel Bruton's tyrosine kinase inhibitor for the treatment of lymphoid malignancies. <i>Expert Opinion on Investigational Drugs</i> , 2012, 21, 355-361.	1.9	34
288	No association between cigarette smoking and incidence of plasma cell myeloma: A meta-analysis of 17 observational studies. <i>American Journal of Hematology</i> , 2012, 87, 729-731.	2.0	8

#	ARTICLE	IF	CITATIONS
289	Human immunodeficiency virus-associated plasmablastic lymphoma. <i>Cancer</i> , 2012, 118, 5270-5277.	2.0	147
290	The Hans algorithm is not prognostic in patients with diffuse large B-cell lymphoma treated with R-CHOP. <i>Leukemia Research</i> , 2012, 36, 413-417.	0.4	45
291	Obesity but not overweight increases the incidence and mortality of leukemia in adults: A meta-analysis of prospective cohort studies. <i>Leukemia Research</i> , 2012, 36, 868-875.	0.4	107
292	R-CHOP versus CHOP in HIV-associated lymphoma: a meta-analysis of prospective studies. <i>Infectious Agents and Cancer</i> , 2012, 7, .	1.2	0
293	Rituximab in combination with chemotherapy versus chemotherapy alone in HIV-associated non-Hodgkin lymphoma: A pooled analysis of 15 prospective studies. <i>American Journal of Hematology</i> , 2012, 87, 330-333.	2.0	27
294	EBV-Positive Diffuse Large B-Cell Lymphoma of the Elderly. , 2012, , 83-98.		1
295	Adult T-Cell Leukemia/Lymphoma in Peru: A Report of 120 Cases. <i>Blood</i> , 2012, 120, 5110-5110.	0.6	4
296	HIV Infection and Cancer: Multi-Institutional Collaboration is the Answer. <i>Journal of AIDS & Clinical Research</i> , 2012, 03, .	0.5	0
297	Survival outcomes in marginal zone lymphomas in the rituximab era: Analysis of the Surveillance, Epidemiology, and End Results (SEER) database.. <i>Journal of Clinical Oncology</i> , 2012, 30, 8045-8045.	0.8	0
298	Hepatitis B Infection Is Associated with an Increased Risk of Non-Hodgkin Lymphoma: A Meta-Analysis.. <i>Blood</i> , 2012, 120, 2658-2658.	0.6	0
299	Higher Body Mass Index Is Associated with an Increased Risk of Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2012, 120, 1605-1605.	0.6	0
300	Survival and Clinicopathological Characteristics of EBV-Positive Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2012, 120, 1588-1588.	0.6	0
301	Plasma Cell Myeloma Causing Hyperammonemia Associated with High Inpatient Mortality. <i>Blood</i> , 2012, 120, 5002-5002.	0.6	8
302	Spontaneous Remission of Chronic Lymphocytic Leukemia, Possibly More Rare Than Previously Reported?. <i>Blood</i> , 2012, 120, 4589-4589.	0.6	0
303	Monocytosis As Prognostic Factor in Aggressive, Non-Primary Cutaneous Peripheral T-Cell Lymphoma: A Study of 251 Cases. <i>Blood</i> , 2012, 120, 1608-1608.	0.6	0
304	Survival of Newly Diagnosed T-Cell Lymphoma (TCL) in the Modern Era: Investigation of Prognostic Factors with Critical Examination of Therapy in a Multicenter US Cohort.. <i>Blood</i> , 2012, 120, 2728-2728.	0.6	2
305	Prognostic Factors in Patients with HIV-Associated Hodgkin Lymphoma: An Analysis of 199 Cases. <i>Blood</i> , 2012, 120, 1528-1528.	0.6	0
306	Vertebral Compression Fractures in Patients with Chronic Lymphocytic Leukemia: Incidence and Risk Factors. <i>Blood</i> , 2012, 120, 4586-4586.	0.6	0

#	ARTICLE	IF	CITATIONS
307	Epstein-Barr Virusâ€“Positive Diffuse Large B-Cell Lymphoma of the Elderly: What We Know So Far. <i>Oncologist</i> , 2011, 16, 87-96.	1.9	99
308	Epsteinâ€“Barr virus-positive diffuse large B-cell lymphoma of the elderly treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone: report of two cases from South America. <i>Leukemia and Lymphoma</i> , 2011, 52, 153-156.	0.6	6
309	HIV-Negative Plasmablastic Lymphoma: Not in the Mouth. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, 185-189.	0.2	93
310	EBV-Positive Diffuse Large B-Cell Lymphoma in Young Immunocompetent Individuals. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, 512-516.	0.2	56
311	Ofatumumab for newly diagnosed and relapsed/refractory chronic lymphocytic leukemia. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 151-160.	1.1	14
312	Plasmablastic Lymphoma: A Systematic Review. <i>Scientific World Journal, The</i> , 2011, 11, 687-696.	0.8	124
313	Plasmablastic lymphoma: Are more intensive regimens needed?. <i>Leukemia Research</i> , 2011, 35, 1547-1548.	0.4	18
314	Prognostic factors in patients with HIVâ€“associated peripheral Tâ€“cell lymphoma: A multicenter study. <i>American Journal of Hematology</i> , 2011, 86, 256-261.	2.0	42
315	Positive HIV ELISA test, autoimmune hemolytic anemia, and generalized lymphadenopathy: A unifying diagnosis. <i>American Journal of Hematology</i> , 2011, 86, 690-693.	2.0	2
316	EBVâ€“positive diffuse large Bâ€“cell lymphoma of the elderly: A case series from Peru. <i>American Journal of Hematology</i> , 2011, 86, 663-667.	2.0	65
317	Different prognostic factors for survival in acute and lymphomatous adult T-cell leukemia/lymphoma. <i>Leukemia Research</i> , 2011, 35, 334-339.	0.4	26
318	Extramedullary relapse of acute myeloid leukemia in a surgical wound. <i>Leukemia and Lymphoma</i> , 2011, 52, 541-543.	0.6	0
319	Meta-Analysis of the Association Between Cigarette Smoking and Incidence of Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2011, 29, 3900-3906.	0.8	29
320	Hematopoietic SCT for adult T-cell leukemia/lymphoma: a review. <i>Bone Marrow Transplantation</i> , 2011, 46, 1039-1044.	1.3	15
321	Association Between Obesity/Overweight and Leukemia: A Meta-Analysis of Prospective Cohort Studies. <i>Blood</i> , 2011, 118, 3588-3588.	0.6	4
322	The Relationship Between Obesity and Lymphoma: A Meta-Analysis of Prospective Cohort Studies. <i>Blood</i> , 2011, 118, 5198-5198.	0.6	3
323	Immunophenotypical Switch versus Tumor Heterogeneity in a Patient with HIV-Associated Diffuse Large B-Cell Lymphoma. <i>Pathology Research International</i> , 2011, 2011, 1-5.	1.4	2
324	Prognostic Factors for Survival in 60 Patients with Classical Hodgkin Lymphoma From Peru. <i>Blood</i> , 2011, 118, 4863-4863.	0.6	10

#	ARTICLE	IF	CITATIONS
325	Clinicopathological Differences Between Asian and Western Patients with De Novo Diffuse Large B Cell Lymphoma Treated with R-CHOP. <i>Blood</i> , 2011, 118, 2665-2665.	0.6	0
326	R-CHOP in the Treatment of EBV-Diffuse Large B-Cell Lymphoma of the Elderly. <i>Blood</i> , 2011, 118, 4988-4988.	0.6	0
327	HIV-Associated Plasmablastic Lymphoma: A Multi-Institutional Study. <i>Blood</i> , 2011, 118, 1589-1589.	0.6	1
328	Association between red blood cell transfusions and development of non-Hodgkin lymphoma: a meta-analysis of observational studies. <i>Blood</i> , 2010, 116, 2897-2907.	0.6	63
329	The role of ofatumumab in the treatment of chronic lymphocytic leukemia resistant to previous therapies. <i>Journal of Blood Medicine</i> , 2010, 1, 1.	0.7	5
330	Prognostic Factors in Chemotherapy-Treated Patients with HIV-Associated Plasmablastic Lymphoma. <i>Oncologist</i> , 2010, 15, 293-299.	1.9	128
331	Lymphopenia as a prognostic factor in patients with peripheral T-cell lymphoma, unspecified. <i>Leukemia and Lymphoma</i> , 2010, 51, 1822-1828.	0.6	38
332	Clinical and pathological differences between human immunodeficiency virus-positive and human immunodeficiency virus-negative patients with plasmablastic lymphoma. <i>Leukemia and Lymphoma</i> , 2010, 51, 2047-2053.	0.6	187
333	Epstein-Barr virus as a prognostic factor in diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2010, 51, 66-72.	0.6	47
334	Complete Remission in Two Cases of Adult T-Cell Leukemia/Lymphoma Treated With Hyper-CVAD: A Case Report and Review of the Literature. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2010, 10, 480-483.	0.2	6
335	Human immunodeficiency virus-associated anaplastic large cell lymphoma. <i>Leukemia and Lymphoma</i> , 2010, 51, 430-438.	0.6	35
336	The Immunohistochemical Profile and Other Prognostic Factors In Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma Treated with R-CHOP. <i>Blood</i> , 2010, 116, 4126-4126.	0.6	2
337	The Association Between Smoking and Hodgkin Lymphoma. <i>Blood</i> , 2010, 116, 2560-2560.	0.6	0
338	Prevalence and Prognostic Factors of EBV-Positive DLBCL of the Elderly In Peru. <i>Blood</i> , 2010, 116, 4166-4166.	0.6	0
339	Quantification of EBV DNA In Whole Blood In Newly Diagnosed Patients with Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2010, 116, 3102-3102.	0.6	0
340	The Risk of Lymphoproliferative Disorders In Patients with Diabetes Mellitus: A Meta-Analysis. <i>Blood</i> , 2010, 116, 3108-3108.	0.6	4
341	Are We Training Our Fellows Adequately in Delivering Bad News to Patients? A Survey of Hematology/Oncology Program Directors. <i>Journal of Palliative Medicine</i> , 2009, 12, 1119-1124.	0.6	49
342	Ofatumumab, a second-generation anti-CD20 monoclonal antibody, for the treatment of lymphoproliferative and autoimmune disorders. <i>Expert Opinion on Investigational Drugs</i> , 2009, 18, 491-500.	1.9	64

#	ARTICLE	IF	CITATIONS
343	Management of hematological malignancies during pregnancy. American Journal of Hematology, 2009, 84, 830-841.	2.0	90
344	EBV-positive diffuse large B-cell lymphoma in a human T-lymphotropic virus type 1 carrier. Infectious Agents and Cancer, 2009, 4, 10.	1.2	12
345	ALK-positive diffuse large B-cell lymphoma: report of four cases and review of the literature. Journal of Hematology and Oncology, 2009, 2, 11.	6.9	72
346	Clinical Characteristics and Outcomes of 102 Patients with Adult T-Cell Leukemia/Lymphoma in Peru.. Blood, 2009, 114, 5001-5001.	0.6	0
347	Clinicopathologic Characteristics of HIV-Associated Peripheral T-Cell Lymphoma.. Blood, 2009, 114, 3924-3924.	0.6	0
348	Clinical Outcome and Survival of EBV-Positive Diffuse Large B-Cell Lymphoma.. Blood, 2009, 114, 5005-5005.	0.6	0
349	The Association Between Red Blood Cell Transfusions and Development of Non-Hodgkin Lymphoma.. Blood, 2009, 114, 1376-1376.	0.6	0
350	Prognostic Factors in Aggressive, Non-Primary Cutaneous Peripheral T-Cell Lymphoma in Peru: A Study of 227 Cases.. Blood, 2009, 114, 5021-5021.	0.6	0
351	Lymphopenia Predicts Survival in Peripheral T-Cell Lymphoma, Unspecified.. Blood, 2009, 114, 1930-1930.	0.6	0
352	Low-Dose Bexarotene Alone or in Combination for the Treatment of Relapsed or Refractory Cutaneous T-Cell Lymphoma.. Blood, 2009, 114, 4790-4790.	0.6	0
353	Images in HIV/AIDS. Fatal HIV-associated anaplastic large-cell lymphoma. Aids Reader, 2009, 19, 19-21.	0.3	3
354	Veltuzumab, an anti-CD20 mAb for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and immune thrombocytopenic purpura. Current Opinion in Molecular Therapeutics, 2009, 11, 200-7.	2.8	25
355	Peripheral T-cell lymphomas in HIV-infected individuals: a comprehensive review. Journal of HIV Therapy, 2009, 14, 34-40.	0.6	10
356	HIV-associated plasmablastic lymphoma: Lessons learned from 112 published cases. American Journal of Hematology, 2008, 83, 804-809.	2.0	266
357	Newer monoclonal antibodies for hematological malignancies. Experimental Hematology, 2008, 36, 755-768.	0.2	75
358	Diabetes and Risk of Non-Hodgkin's Lymphoma. Diabetes Care, 2008, 31, 2391-2397.	4.3	131
359	Non-Hodgkin Lymphoma and Smoking: A Meta-Analysis of Case-Control Studies. Blood, 2008, 112, 5292-5292.	0.6	1
360	Epstein-Barr Virus Status as Prognostic Factor in Nodal Diffuse Large B-Cell Lymphoma in Elderly Patients. Blood, 2008, 112, 5301-5301.	0.6	0

#	ARTICLE	IF	CITATIONS
361	Immunohistochemical Expression of Germinal Center and Non-Germinal Center Markers in Primary Gastric Diffuse Large B-Cell Lymphoma. Blood, 2008, 112, 5276-5276.	0.6	0
362	ALK-Positive Diffuse Large B-Cell Lymphoma: Report of Four Cases from Peru. Blood, 2008, 112, 4967-4967.	0.6	0
363	Low-Dose Bexarotene and Phototherapy or Interferon Alfa-2a in the Treatment of Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma. Blood, 2008, 112, 5010-5010.	0.6	1
364	Immunohistochemical Expression Pattern of Germinal Center and Non-Germinal Center Markers in Age-Related Epstein Barr Virus-Associated B-Cell Lymphoproliferative Disorder. Blood, 2008, 112, 5289-5289.	0.6	0
365	Smoking and Hodgkin Lymphoma: A Meta-Analysis. Blood, 2008, 112, 4829-4829.	0.6	0
366	AIDS-related lymphomas: the Rhode Island experience. Medicine and Health, Rhode Island, 2008, 91, 332-4.	0.1	0
367	Noteworthy Features of HIV-associated T-cell Non-Hodgkin lymphoma. HIV and AIDS Review, 2007, 6, 26-30.	0.1	0
368	HIV-Associated NK/T-Cell Lymphomas: A Review of 93 Cases.. Blood, 2007, 110, 3457-3457.	0.6	2
369	Consenso del Grupo de Estudio Latinoamericano de Linfoproliferativos (GELL) para el manejo del Linfoma en estado de Pandemia SARS CoV-2 / COVID 19. Revista Colombiana De Cancerología, 0, 24, .	0.0	2